Medicare AdvantageBilling CodesMedium impact
MA11.002q, Hematopoietic Stem Cell Transplantation
Independence Blue Cross·Oncology, Hematology, Transplant Surgery +1 more·Medical Policy
Effective date
Oct 1, 2026
We identified it
Oct 2, 2026
Summary
Independence Blue Cross updated MA11.002q to reflect HCPCS code changes effective October 1, 2026. New code J3406 (omidubicel-onlv injection) was added to the hematopoietic stem cell transplantation policy, while two unclassified drug/biologic codes (C9399, J3590) were removed. This is a coding maintenance update to align with annual HCPCS updates; no coverage criteria changes were made.
Action Required
By October 1, 2026: Billing team must update billing system and claim submission software to recognize the new HCPCS code J3406 (omidubicel-onlv) as a covered therapeutic agent under MA11.002q for hematopoietic stem cell transplant cases. Remove codes C9399 and J3590 from billing templates and edits for this policy line. Update internal billing guidelines and provider education materials to reflect that omidubicel-onlv is no longer billed under unclassified biologics. Verify that claims submitted with J3406 are routed correctly for prior authorization review if required by patient's Medicare Advantage plan. Test system changes before effective date to prevent claim rejections or delays.